Tenosynovial Giant Cell Tumor

Slide 1 · Tenosynovial Giant Cell Tumor

Localized and diffuse types: pathogenesis, morphology, clinical patterns

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Locate the lesion within the joint, tendon sheath, or bursa

Explain how a CSF1 alteration produces a macrophage-rich tumor

Distinguish localized from diffuse growth patterns

Correlate morphology with clinical behavior and treatment limits

Slide 3 · Joint tumors: The diagnostic setting

Initial question

Is the lesion reactive or neoplastic — and where does it arise?

Joint- and tendon-sheath lesions are often reactive rather than neoplastic

Ganglion and synovial cysts are common mimics in this compartment

True primary joint neoplasms are uncommon and frequently benign

Slide 4 · The central definition

Tenosynovial giant cell tumor is a benign synovium-associated neoplasm.

Origin: Synovial lining of joints, tendon sheaths, or bursae

Two biologically linked patterns: Localized and diffuse

Benign designation does not exclude locally damaging growth

Slide 5 · Three potential sites of origin

Villous/nodular synovium (schematic)

Joint synovium

Tendon sheath

Bursal synovial lining

Slide 6 · Two types of tenosynovial giant cell tumor

Feature

Localized

Diffuse

Typical form

Discrete nodule

Extensive synovial proliferation

Common setting

Hand tendon sheath

Large joint

Clinical theme

Painless, slow growth

Mechanical joint symptoms

Course

Less recurrence

Recurrence common

Slide 7 · Age distribution

Both localized and diffuse types are most often diagnosed in the second through fourth decades

Age is a contextual clinical clue—not sufficient by itself for diagnosis

Anatomic location and growth pattern remain more discriminating features

Slide 8 · Historical terminology

“Pigmented villonodular synovitis” is the former name for diffuse TGCT.

“Pigmented”: Prominent hemosiderin-containing cells

“Villous/nodular”: Folded and nodular synovium

Modern terminology emphasizes a neoplasm rather than merely synovitis

Slide 9 · Diffuse type: The joint-centered pattern

Surface expansion with subsynovial spread (schematic)

Expansive synovial involvement

Tendency to involve larger joints

Potential invasion of subsynovial tissue

Slide 10 · Localized type: A tendon-sheath nodule

Nodule adjoining tendon sheath (schematic)

Discrete nodular mass

Usually attached to tendon sheath

Hand is a characteristic location

Slide 11 · Why anatomical context matters

Question

Localized presentation

Diffuse presentation

What is found?

A single nodule

Synovial folds and nodules

Where?

Wrist and finger sheaths

Often knee

Clinical clue

Slow painless enlargement

Pain, locking, recurrent swelling

Slide 12 · CSF1 biology is the pathogenetic core

The tumor recruits many macrophages; The neoplastic cells need not be numerically dominant.

Genomic rearrangement alters CSF1 expression

Neoplastic cells secrete excess M-CSF

Macrophages expand in response to this signal

Slide 13 · A genetic event initiates the process

T(1;2)

Somatic reciprocal translocation

→

COL6A3

Promoter moved before CSF1 coding sequence

→

CSF1

Overexpressed by tumor cells

Schematic of promoter rearrangement; Not a depiction of chromosome band anatomy.

Slide 14 · What the translocation specifies

T(1;2)(p13;q37) juxtaposes the COL6A3 promoter and CSF1 coding region.

Somatic: Acquired in the tumor rather than inherited by definition

Involves chromosome 1 and chromosome 2

Occurs in the pathogenesis described for both morphologic types

Slide 15 · Promoter-to-effector relationship

COL6A3 promoter

New upstream regulatory context

→

CSF1 coding region

Increased gene expression

→

M-CSF

Secreted signaling molecule

The Robbins account describes increased expression, not a new chimeric CSF1 protein.

Slide 16 · CSF1 and M-CSF: One molecular axis

CSF1 is the gene encoding macrophage colony-stimulating factor (M-CSF)

In the rearranged tumor cells, M-CSF is overexpressed and secreted

Its biological effects include stimulation of macrophage proliferation

Slide 17 · How a minority builds a large lesion

Neoplastic cells

Source of secreted M-CSF

→

M-CSF signal

Autocrine and paracrine activity

→

Macrophage expansion

Prominent non-neoplastic cellular infiltrate

A macrophage-rich mass can be driven by a comparatively small altered cell population.

Slide 18 · Autocrine and paracrine signaling

Mode

Direct target

Meaning in the tumor

Autocrine

Source cell itself

M-CSF acts on secreting neoplastic cells

Paracrine

Nearby cells

M-CSF acts on recruited macrophages

Slide 19 · Tumor composition: Neoplastic minority

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

Polygonal neoplastic cells are relatively few

Numerous macrophages surround them

Cellularity alone cannot identify the clone

Slide 20 · A macrophage-rich microenvironment

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

M-CSF stimulates macrophage proliferation

Macrophage accumulation dominates the tissue response

Macrophages may occur in multinucleated forms

Slide 21 · Morphology follows the signaling biology

Abundant macrophages are a biological consequence of CSF1 pathway activity.

The molecular driver resides in neoplastic tumor cells

The microscopic field includes many secondary participants

This resolves the apparent mismatch between clone size and mass size

Slide 22 · Neoplastic and recruited components

Property

Neoplastic tumor cells

Recruited macrophages

Relative abundance

Minority

Densely infiltrating population

Appearance

Polygonal; Synoviocyte-like

Hemosiderin-rich or foamy; Can be giant

Role

Overexpress M-CSF

Respond to CSF1 pathway signal

Slide 23 · Both variants share the molecular mechanism

The same CSF1-associated rearrangement in localized and diffuse forms

This is consistent with their common microscopic cellular components

The major distinction is growth distribution and clinical course

Slide 24 · The gross specimen: Color as a clue

TGCT is described grossly as red-brown to orange-yellow.

Pigment-laden macrophages contribute to the characteristic appearance

Diffuse disease produces a folded or nodular synovial surface

Color is helpful but not a stand-alone diagnostic criterion

Slide 25 · Diffuse gross morphology: Villous synovium

Villous/nodular synovium (schematic)

Smooth synovium becomes a tangled mat

Red-brown folds and finger-like projections

Multiple nodules can coexist

Slide 26 · Diffuse involvement is architectural

Surface expansion with subsynovial spread (schematic)

Surface proliferation extends along synovium

Subsynovial infiltration is described

Distribution contributes to local complexity

Slide 27 · Localized gross morphology: Circumscribed

Nodule adjoining tendon sheath (schematic)

Well-defined localized nodule

Often arises adjacent to a tendon sheath

Distinct from widespread joint-surface replacement

Slide 28 · A pedicle can connect the mass to synovium

A solid aggregate may remain attached to synovium by a pedicle

Pedunculation is an architectural finding, not proof of benignity alone

Interpret attachment together with the cell population

Slide 29 · Recognizing synoviocyte-like cells

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

Moderately sized polygonal neoplastic cells

Appearance resembles synoviocytes

These cells form a minority of the lesion

Slide 30 · Macrophages with hemosiderin

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

Hemosiderin may accumulate within macrophages

Pigmented cells help explain red-brown appearance

Not every pigmented cell is a neoplastic cell

Slide 31 · Foamy macrophages

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

Macrophages can contain foamy lipids

Foamy histiocytes occur alongside other cell types

Mixture is expected in both variants

Slide 32 · Multinucleated giant cells

Schematic — not a histologic specimen

Neoplastic

Macrophage

Giant cell

Macrophages may become multinucleated

Giant cells are a conspicuous component

Presence alone does not define the neoplastic clone

Slide 33 · Older lesions may become fibrotic

Fibrosis is part of the described histologic evolution of TGCT.

Longer-standing tumors need not show only a cellular architecture

Fibrotic regions may coexist with macrophage-rich areas

A limited field may underrepresent the whole lesion

Slide 34 · Microscopic checklist

Component

Expected observation

Interpretive significance

Tumor population

Polygonal synoviocyte-like cells

Neoplastic minority

Histiocytes

Hemosiderin or foamy lipid

Macrophage recruitment

Giant cells

Multinucleated forms

Macrophage-lineage component

Stroma

Possible fibrosis

Older-lesion change

Slide 35 · Histologic geography differs

Finding

Localized TGCT

Diffuse TGCT

Macrophage infiltrate

Present

Present

Giant cells

Can be present

Can be present

Overall growth

Discrete / circumscribed

Synovial spread and subsynovial invasion

Slide 36 · Pathologic interpretation requires distribution

The same basic cell mixture can occur in two different architectural patterns.

Do not classify type using macrophages or giant cells alone

Examine whether growth is discrete or diffusely synovial

Integrate specimen anatomy with the clinical presentation

Slide 37 · Gross–microscopic correlation

Gross appearance

Tissue correlate

Red-brown tissue

Hemosiderin-containing macrophages

Villous/nodular synovium

Broad surface proliferation

Circumscribed mass

Localized nodular architecture

Fibrotic older lesion

Stromal fibrosis

Slide 38 · Diffuse TGCT: Knee predominance

That 80% of diffuse presentations occur in the knee.

The knee is therefore a high-yield site in clinical vignettes

Other large joints can still be involved

Site is a probability clue—not a diagnostic criterion

Slide 39 · Diffuse clinical presentation

Pain is a common presenting symptom

Locking is described, consistent with intra-articular mechanical disturbance

Recurrent swelling may dominate the clinical history

Some patients also have a palpable mass

Slide 40 · Why diffuse TGCT mimics monoarthritis

Clinical feature

Potential interpretation

Recurrent single-joint swelling

May be mistaken for monoarticular arthritis

Pain with episodic locking

Suggests an intra-articular process

Mass or erosive extension

May suggest another neoplasm

Slide 41 · Atypical but important: Extension and erosion

Some diffuse lesions erode into adjacent bone

Soft-tissue extension can also occur

Locally destructive growth may resemble other neoplasms

Benign classification must not be confused with harmless behavior

Slide 42 · Diffuse lesions frequently recur

Recurrence is a prominent clinical problem for the diffuse form.

Broad synovial distribution complicates disease extent

A locally infiltrative pattern coexists with benign histologic designation

Clinical surveillance is therefore a relevant management consideration

Slide 43 · Localized disease: The wrist and fingers

Nodule adjoining tendon sheath (schematic)

Solitary nodule

Slow growing and usually painless

Frequent in tendon sheaths of digits or wrist

Slide 44 · Localized TGCT: Expected behavior

Most often presents as a discrete, slow-growing painless mass

Bone erosion is less common than in diffuse disease

Recurrence is also less common than in diffuse disease

Slide 45 · Comparison of expected clinical behavior

Feature

Localized

Diffuse

Mass pattern

Solitary nodular mass

Broad synovial disease

Symptoms

Often painless

Pain, locking, swelling

Bone erosion

Less common

Can occur

Recurrence

Less common

Common

Slide 46 · Benign does not imply biologically inert

TGCT illustrates why neoplasm grade and local impact are separate questions.

The tumor is classified as benign

Diffuse lesions may erode bone and infiltrate soft tissues

Treatment decisions therefore consider function and morbidity

Slide 47 · Ganglion cyst versus TGCT

Aspect

Ganglion cyst

Tenosynovial giant cell tumor

Category

Degenerative cystic lesion

Benign neoplasm

Tissue content

Synovial-like fluid

Cellular mass

Wall / cells

No true cell lining

Neoplastic cells + macrophages

Common site

Near wrist joint or sheath

Hand sheath in localized TGCT

Slide 48 · Synovial cyst versus TGCT

Aspect

Synovial cyst

Tenosynovial giant cell tumor

Origin

Synovial herniation / enlarged bursa

Synovium-associated neoplasm

Structure

Synovium-like lining, fluid

Tumor-cell and macrophage mixture

Context

Can occur with RA or OA

Neoplastic CSF1 signaling described

Slide 49 · Compartment-based differential reasoning

The location of a nodule is a starting point, not the diagnosis.

A wrist mass can be a ganglion or localized TGCT

Fluid-filled lined/unlined cysts differ from a cellular neoplasm

Specimen architecture and cellular composition resolve the distinction

Slide 50 · A practical tissue-identification sequence

Localize

Joint, bursa, or tendon sheath?

→

Classify pattern

Discrete nodule or diffuse synovium?

→

Inspect cells

Synoviocyte-like cells and macrophages?

→

Integrate

Clinical pattern with morphology

This is an educational interpretation pathway; No diagnostic test-performance claims are implied.

Slide 51 · Excision remains the central treatment

Surgical excision is described as the mainstay of treatment

The extent and distribution of disease matter for treatment impact

A localized nodule and widespread synovial disease pose different practical challenges

Slide 52 · Why CSF1-directed therapy is plausible

CSF1 overexpression

Neoplastic-cell signal

→

Macrophage pathway

CSF1-mediated cellular response

→

Pathway antagonism

Pharmacologic therapeutic strategy

Mechanism-to-therapy rationale; Not a drug-specific efficacy or dosing claim.

Slide 53 · A major therapeutic constraint: Liver toxicity

Antagonists of M-CSF signaling can cause severe hepatotoxicity.

Them as effective, but not routine therapy for every patient

Risk–benefit assessment is essential

Use is restricted to cases in which surgery risks substantial morbidity or functional impairment

Slide 54 · Treatment principles by disease context

Clinical situation

Management implication

Resectable tumor

Surgical excision is the mainstay

Surgery may cause major functional loss

CSF1-pathway antagonism may be considered

Considering systemic antagonism

Severe hepatotoxicity risk must be weighed

Slide 55 · Case 1: Recurrent knee symptoms

Illustrative case

An adult has recurrent knee swelling, pain, and locking. A synovium-based nodular proliferation is identified.

Question: Which TGCT growth pattern is most consistent with the presentation?

Slide 56 · Case 1: Interpretation

Illustrative case

A joint-wide, folded synovium with macrophage-rich tumor is encountered.

Diffuse TGCT is favored: Large-joint pattern, synovial spread, and characteristic symptoms.

Slide 57 · Case 2: Slow-growing finger mass

Illustrative case

An adult has a solitary, painless, slowly enlarging nodule closely associated with a finger tendon sheath.

Question: What morphology and clinical behavior are most expected?

Slide 58 · Case 2: Interpretation

Illustrative case

The excised lesion is well circumscribed and contains synoviocyte-like cells with macrophages and giant cells.

Localized TGCT fits; Bone erosion and recurrence are less common than in diffuse disease.

Slide 59 · Case 3: A pigmented, cell-rich mass

Illustrative case

A microscopic sample contains many hemosiderin-laden macrophages and multinucleated giant cells. Only scattered polygonal synoviocyte-like cells are present.

Question: Which population is expected to carry the neoplastic CSF1 alteration?

Slide 60 · Case 3: Interpretation

Illustrative case

The abundant macrophages are the most obvious cells under the microscope.

The relatively rare neoplastic cells drive M-CSF expression and macrophage recruitment.

Slide 61 · High-yield consolidation: The two types

Dimension

Localized TGCT

Diffuse TGCT

Gross

Well-circumscribed nodule

Villous / nodular synovium

Preferred compartment

Tendon sheath of hand

Large joint; Often knee

Microscopy

Tumor cells + macrophages

Shared mixture; Infiltrative extent

Clinical course

Less erosion / recurrence

Pain, swelling, locking; Recurrence

Slide 62 · The complete pathogenetic model

Chromosomal rearrangement

COL6A3 promoter before CSF1

→

M-CSF secretion

Tumor-cell overexpression

→

Macrophage-rich mass

Hemosiderin, foam cells, giant cells

→

Local phenotype

Nodular or diffuse synovial growth

Interpretation links directly to the morphologic and clinical descriptions.

Slide 63 · Five defensible conclusions

TGCT is a benign tumor of synovium-related structures

Localized and diffuse types share a CSF1-based mechanism

The true neoplastic population can be a minority of the mass

Diffuse disease is synovial, locally damaging, and prone to recurrence

Surgery is central; CSF1 antagonism is limited by toxicity

Slide 64 · Primary reference

Robbins, Cotran & Kumar

Pathologic Basis of Disease · 11th edition

“Tenosynovial Giant Cell Tumor”

Gross and microscopic sketches in this lecture are original editable schematics, not actual pathology specimens.